Dear customer, we are sorry but your browser doesn't support all necessary features for good site view. Please switch to one of the modern browsers (Chrome, Safari, Firefox).
Our CompaniesNewsroomInsights

About PPF Group

About UsPeople and statutory bodiesFinancial results & statementsReports and documents

Social responsibility

Social responsibilitySustainability
For MediaContactsCareers
cs

News to Email

Get the latest press releases, interviews, podcasts, and insights. 

Subscribe To News

Follow us

For Media

  • Press Releases
  • Interviews and Podcasts
  • Subscribe To News
  • Downloads
  • Contacts

MAY BE OF INTEREST

  • Our Companies
  • Newsroom
  • Insights

Contacts

  • PPF Group Companies
  • Terms of use
  • Data protection
  • Sitemap
  • Cookies policy

2026 © PPF Group

Most often you are looking for

Annual ReportsInsightsVisions and StrategiesPress Releases

  • Insights

  • Biotech Market / Business Intelligence

Sotio Biotech

15/8/2025

June 2025 Biotechnology: Review of news from the most innovative therapeutic areas and the business development transactions

by Jakub Jarolím, Business Intelligence Department

Share on social networks

Share on social networks

Print

Copy link

Market

President Trump wants interest rate cut to 1% and would “love” if Fed’s Powell resigned

US stocks took a breather end of June as the tenuous Israel-Iran cease fire continued to hold. Fed Chair Jerome Powell said inflation in goods prices is expected to go up due to Trump's tariffs. Trump said he wants interest rate cut to 1% and that he would “love” if Powell resigned.

News detail

Antibody-Drug Conjugates

FDA approved Datroway for patients with pre-treated advanced EGFR-mutated NSCLC

News detail

Interleukin-15 and Interleukin-2

Rezpegaldesleukin meets primary and key secondary endpoints in REZOLVE-AD Phase 2

Nektar announced statistically significant data from the 16-week induction period of the ongoing Phase 2b REZOLVE-AD study of investigational rezpegaldesleukin, an IL-pathway agonist and regulatory T-cell (Treg) proliferator.

News detail

Cell Therapies

JNJ's dual-targeting CAR-T shows first encouraging results in large B-cell lymphoma

BMS announced that FDA approved label updates for both of its CAR T cell therapies, Breyanzi (liso-cel) for the treatment of large B cell lymphoma (LBCL) and other lymphomas and Abecma (ide-cel) for the treatment of multiple myeloma. These label updates reduce certain patient monitoring requirements and remove the Risk Evaluation and Mitigation Strategy (REMS) programs that had been in place since each product was initially approved.

News detail

DISCLAIMER / SOTIO

Legal Notice 6/25

News detail